Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST) | MicrobiomeTrials← Back to trialsNCT04739202
Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST)
CompletedPHASE2INTERVENTIONAL
Trial Details
Start: 2021-03-19Est. Completion: 2026-06-04
Enrollment target: 54 participants Locations- Dijon - Centre Georges-Francois Leclerc, Dijon, France
- Hcl - Hopital Edouard Herriot, Lyon, France
- Aphm - Hopital La Timone, Marseille, France
- Aphp - Hopital Saint-Louis, Paris, France
- Aphp - Hopital Pitie Salpetriere, Paris, France
- Bordeaux - Hopital Haut-Leveque, Pessac, France
- Hcl - Centre Hospitalier Lyon Sud, Pierre-Bénite, France
- Toulouse - Iuct Rangueil-Larrey, Toulouse, France
Other microbiome trials you might be interested in
Chemotherapy Effect
This study focuses on patients with H. pylori-positive resectable locally advanced adenocarcinoma of the gastric and oes…
Guangzhou, ChinaEst. completion Dec 28, 2026
Gastro-Oesophageal Cancer
To determine if the regorafenib and nivolumab combination (RegoNivo) improves overall survival compared with current sta…
Scottsdale, United StatesCompleted Jan 14, 2025
Gastric AdenocarcinomaGastroesophageal Junction (GEJ) AdenocarcinomaPancreatic Adenocarcinoma
Claudin 18.2 protein, or CLDN18.2 is a protein found on cells in the digestive system. It is also found on some tumors. …
Orange, United StatesEst. completion May 31, 2028